→ Are you confident you are managing drug interference effectively?
Many consider drug interference as one of the toughest challenges in immunogenicity testing. Hear case studies from Amgen, Merrimack Pharmaceuticals, and Human Genome Sciences as these scientists share method validation techniques and lessons learned for handling drug interference with the diversity of therapeutic products in development.
→ Can you accurately evaluate the downstream impact of your immunogenicity data and establish clinical relevance for overall study interpretation?
Hear case studies from Eli Lilly and Biogen Idec on how to handle complicated immunogenicity assessments and the overall impact of these results upon clinical studies. Be ready to share your own lessons learned and ask questions of industry colleagues regarding strategies and solutions for data interpretation and establishing clinical relevance.
→ Do you need clarity on the induction of immunological tolerance to proteins?
To achieve the full potential of biologicals as therapeutic products, alternative approaches for eliminating immunogenicity are essential. Spend an afternoon with experts from Pfizer, State University of NY at Buffalo, Genzyme, and the University School of Medicine to discuss the details and challenges for tolerance induction to therapeutic proteins.
Join these sessions and many more at the longest running and the largest Immunogenicity event of the year. Visit our website to view the finalized agenda and to place your registration.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment